Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women

BACKGROUND AND OBJECTIVES: Advanced estrogen receptor-positive (ER+) breast cancer is currently treated with endocrine therapy. Elacestrant is a novel, nonsteroidal, selective estrogen receptor degrader with complex dose-related ER agonist/antagonist activity that is being developed as a treatment o...

Descripción completa

Detalles Bibliográficos
Autores principales: Conlan, Maureen G., de Vries, Erik F. J., Glaudemans, AWJM, Wang, Yamei, Troy, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511284/
https://www.ncbi.nlm.nih.gov/pubmed/32661909
http://dx.doi.org/10.1007/s13318-020-00635-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511284/
https://www.ncbi.nlm.nih.gov/pubmed/32661909
http://dx.doi.org/10.1007/s13318-020-00635-3

Ejemplares similares